Related Experiment Video
Updated: May 5, 2026
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Harnessing Targeted Protein Degradation for Developing Brain Cancer Therapy
Osaid Muhammad1, Sophie White1,2, Carina Dumo1,2,3
1Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Abstract:
Neoplasms of the brain remain challenging to treat due to their complex heterogeneity and the presence of physiological barriers that confer the brain its immune privileged status. Extensive drug discovery efforts have focused on small molecule inhibitors targeting dysregulated cellular pathways to improve patient survival and quality of life. However, these approaches often face limitations, including incomplete efficacy arising from pathway redundancy and compensatory mechanisms. Induced protein degradation has emerged as a novel therapeutic strategy with a distinct mechanism of action, offering the potential to overcome many of the shortcomings associated with conventional inhibition. Several classes of degraders have now advanced into clinical trials for various diseases including cancers. This review provides an overview of the current state of protein degradation technologies as applied to brain cancer therapy, with a particular focus on three modalities: PROTACs, molecular glues, and LYTACs. Key aspects discussed include their synthesis, biological evaluation, and translational potential. The field offers an opportunity to develop meaningful therapies and stands at the precipice of breakthroughs that could transform the treatment landscape for brain cancer patients.
Insights
Protein degradation technologies like PROTACs offer new ways to treat brain cancers by degrading disease-causing proteins. This approach may overcome limitations of traditional small molecule inhibitors for better patient outcomes.
Area of Science:
- Oncology
- Neuroscience
- Drug Discovery
Background:
- Brain neoplasms present significant treatment challenges due to tumor heterogeneity and the brain's immune-privileged status.
- Conventional small molecule inhibitors often show incomplete efficacy because of pathway redundancy and compensatory mechanisms.
- Induced protein degradation is an emerging therapeutic strategy with a novel mechanism of action.
Purpose of the Study:
- To review the current landscape of protein degradation technologies for brain cancer therapy.
- To focus on Proteolysis-Targeting Chimeras (PROTACs), molecular glues, and Lysosome-Targeting Chimeras (LYTACs).
- To discuss the synthesis, biological evaluation, and translational potential of these degradation modalities.
Main Methods:
- Literature review of protein degradation technologies.
- Focus on PROTACs, molecular glues, and LYTACs in the context of brain cancer.
- Analysis of synthesis, biological evaluation, and translational aspects.
Main Results:
- Protein degradation offers a promising approach to overcome limitations of conventional therapies for brain tumors.
- PROTACs, molecular glues, and LYTACs are key modalities with potential therapeutic applications.
- These technologies are advancing towards clinical trials for various cancers, including brain neoplasms.
Conclusions:
- Protein degradation technologies represent a significant advancement in the development of novel brain cancer therapies.
- The field holds promise for overcoming treatment resistance and improving patient outcomes.
- Breakthroughs in induced protein degradation could transform the therapeutic landscape for brain cancer patients.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...